Acrivon Therapeutics Reports Strong ACR-368 Data in Serous Endometrial Cancer, Expands Pipeline
Event summary
- ACR-368 Phase 2b trial shows 52% confirmed overall response rate in serous endometrial cancer.
- Company initiates Arm 3 and plans Arm 4 for ACR-368 Phase 2b study in all-comer serous EC subjects.
- ACR-2316 Phase 1 data shows promising clinical activity in heavily pre-treated lung cancer subjects.
- Cash position of $118.6 million expected to fund operations into Q2 2027.
The big picture
Acrivon Therapeutics is leveraging its proprietary AP3 platform to drive precision oncology, with ACR-368 showing promising results in a high-unmet-need indication. The company's strategic focus on serous endometrial cancer, coupled with its expanding pipeline, positions it to capitalize on the growing demand for targeted therapies. The financial runway into 2027 provides a buffer for clinical and regulatory milestones.
What we're watching
- Clinical Validation
- Whether ACR-368 can sustain its high response rate in larger, more diverse patient populations.
- Regulatory Pathway
- The pace at which Acrivon can secure regulatory approvals for ACR-368, particularly in the EU.
- Pipeline Progress
- How quickly ACR-2316 and ACR-6840 advance through clinical trials and demonstrate efficacy.
Related topics